MannKind Corp.
MannKind Corporation (MNKD) is a small-cap biopharmaceutical company best known for Afrezza, an inhalable insulin product for people with diabetes. Investors should know MannKind’s value proposition centres on its inhalation delivery technology and commercial efforts to grow Afrezza sales, pursue new indications and explore licensing or partnership opportunities. Financial performance can be uneven: revenue depends heavily on product uptake, distribution arrangements and any new regulatory or reimbursement developments. The company has R&D and regulatory risk typical of biotech firms, plus market competition from other diabetes therapies. MannKind does not currently offer a dividend, and its shares can be volatile. This summary is for general educational purposes only and is not personalised investment advice; always consider your risk tolerance and do further research or consult a professional before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MannKind's stock, with a target price of $9.69, indicating strong growth potential.
Financial Health
MannKind Corp. is generating strong revenue and profits, supported by healthy cash flow and margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MNKD
Pharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: October 10, 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Afrezza revenue potential
Afrezza is the main commercial asset and could drive growth if uptake or label expansion improves, although sales trends have been uneven and outcomes are uncertain.
Inhaled delivery focus
Proprietary inhalation technology differentiates the company and may enable licensing opportunities, but technical, regulatory and commercial hurdles remain.
Partnerships & markets
Collaborations and market access are important for scaling reach; changes in reimbursement or competitive diabetes therapies can materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
